Sutro Biopharma (STRO) to Release Earnings on Thursday

Key Points

• Sutro Biopharma will report Q1 2026 results before the market opens on Thursday, May 14, with analysts expecting EPS of ($2.7363) and revenue of $8.893 million; an earnings call is scheduled for 4:00 PM ET.
• The stock opened at $37.69 (up ~1.0%), with a market cap of $624.5M, a 1‑year range of $6.74–$39.74, and 50/200‑day moving averages of $26.50/$16.93.
• Analysts have grown more bullish—MarketBeat shows a consensus rating of “Moderate Buy” and a target price of $40.78 amid multiple upgrades—yet forecasts also project multi‑year net losses, underscoring ongoing cash‑burn and clinical/partnership risk; institutional investors own ~97% of the stock.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) is expected to post its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Sutro Biopharma to post earnings of ($2.7363) per share and revenue of $8.8930 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Sutro Biopharma Trading Up 1.0%

NASDAQ STRO opened at $37.69 on Thursday. The firm has a market cap of $624.52 million, a PE ratio of -1.44 and a beta of 1.63. Sutro Biopharma has a 1-year low of $6.74 and a 1-year high of $39.74. The stock has a 50-day moving average of $26.50 and a 200-day moving average of $16.93.

Hedge Funds Weigh In On Sutro Biopharma

A number of institutional investors have recently added to or reduced their stakes in the company. State of Tennessee Department of Treasury bought a new position in shares of Sutro Biopharma during the fourth quarter valued at $86,000. Opaleye Management Inc. purchased a new position in Sutro Biopharma in the 4th quarter worth approximately $2,206,000. Balyasny Asset Management L.P. purchased a new stake in Sutro Biopharma during the 4th quarter valued at $2,662,000. ADAR1 Capital Management LLC bought a new stake in shares of Sutro Biopharma in the 4th quarter worth $776,000. Finally, Jane Street Group LLC purchased a new position in shares of Sutro Biopharma in the fourth quarter worth $265,000. Institutional investors own 96.99% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on STRO shares. Wall Street Zen upgraded shares of Sutro Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, March 28th. Mizuho set a $50.00 price objective on shares of Sutro Biopharma and gave the company an "outperform" rating in a research report on Thursday, April 30th. Wells Fargo & Company upgraded shares of Sutro Biopharma from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $8.00 to $27.00 in a report on Tuesday, March 24th. Citizens Jmp upped their price target on Sutro Biopharma from $35.00 to $41.00 and gave the company a "market outperform" rating in a research report on Thursday, April 23rd. Finally, Lifesci Capital upgraded Sutro Biopharma to a "strong-buy" rating in a research report on Friday, May 1st. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $40.78.

More Sutro Biopharma News

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Truist upgraded Sutro to a "Strong-Buy", providing a clear buy-side catalyst that likely boosted investor demand. Zacks
• Positive Sentiment: Lifesci Capital reiterated a "Strong-Buy" stance on STRO and published refreshed analyst coverage, which supports continued bullish sentiment among institutional and retail investors. MarketBeat
• Neutral Sentiment: Lifesci released a full set of quarterly and multi-year EPS projections for STRO (Q1–Q4 2026, FY2026–FY2030 and interim 2027–2029 quarters). These updates provide additional modeling detail for investors but do not by themselves change company fundamentals. MarketBeat
• Negative Sentiment: The Lifesci model projects continued material net losses across multiple years (examples: FY2026 ≈ -$6.60/share; FY2027 ≈ -$5.45/share; Lifesci/consensus FY current-year around -$9.17). Those persistent negative EPS forecasts highlight ongoing cash-burn/clinical-development risk, which could pressure valuations if clinical or partnership news lags. MarketBeat

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.